News

The eight-month angiographic follow-up continued to demonstrate reduction in late lumen loss and neointimal hyperplasia formation. In-stent late lumen loss was 0.31 ± 0.25 mm, neointimal volume obstruction

The technology was developed in the laboratory of Andrew Lever at the University of Cambridge. Following the acquisition of the Cell Genesys’s lentiviral patent portfolio in 2007 by

Under the terms of this non-exclusive agreement, Hydromer will supply its proprietary and patented Hydromer hydrophilic coatings for use on various Pebax plastic neurovascular and cardiovascular catheters. This

On admission to the trial, patients were randomized on a two-to-one ratio into the treatment versus control groups with 26 patients receiving MyoCell therapy and 14 patients in

The GeneSys system is claimed to be the first on the market to offer a fully automated approach for newborn screening while providing positive identification for all major

The pharmacokinetic study was conducted in healthy human volunteers and compared the drug exposure profile of arbaclofen, under both fasted and fed conditions, following a single oral administration

Initially, clinical results for three different doses of the active ingredient 5-aminolevulinic acid (ALA) and placebo are compared. Following the treatment and two-month observation of 80 patients enrolled

The assets consisted of, rifalazil, a Phase II antibiotic, a library of novel rifamycin compounds, and a clinical stage superoxide dismutase mimetic (SODm) and a library of SODm

The validation of the marketing authorization application (MAA) for Xyotax initiates the marketing approval review process, which generally takes 15 to 18 months. The EMEA agreed that switching